ATE517617T1 - Behandlung von parkinson erkrankung mit kape - Google Patents

Behandlung von parkinson erkrankung mit kape

Info

Publication number
ATE517617T1
ATE517617T1 AT02786994T AT02786994T ATE517617T1 AT E517617 T1 ATE517617 T1 AT E517617T1 AT 02786994 T AT02786994 T AT 02786994T AT 02786994 T AT02786994 T AT 02786994T AT E517617 T1 ATE517617 T1 AT E517617T1
Authority
AT
Austria
Prior art keywords
kape
parkinson
disease
treatment
neurodegenerative
Prior art date
Application number
AT02786994T
Other languages
English (en)
Inventor
Yansheng Du
Martin Farlow
Ruyu Du
Original Assignee
Yansheng Dr Du
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yansheng Dr Du filed Critical Yansheng Dr Du
Application granted granted Critical
Publication of ATE517617T1 publication Critical patent/ATE517617T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT02786994T 2001-12-10 2002-12-10 Behandlung von parkinson erkrankung mit kape ATE517617T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33921501P 2001-12-10 2001-12-10
PCT/US2002/039458 WO2003053425A1 (en) 2001-12-10 2002-12-10 Treatment of neurodegenerative and cardiovascular disorders

Publications (1)

Publication Number Publication Date
ATE517617T1 true ATE517617T1 (de) 2011-08-15

Family

ID=23328006

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02786994T ATE517617T1 (de) 2001-12-10 2002-12-10 Behandlung von parkinson erkrankung mit kape

Country Status (9)

Country Link
US (2) US20030139458A1 (de)
EP (1) EP1461025B1 (de)
JP (1) JP4511183B2 (de)
CN (1) CN100358515C (de)
AT (1) ATE517617T1 (de)
AU (1) AU2002351341A1 (de)
CA (1) CA2466928A1 (de)
TW (1) TWI335220B (de)
WO (1) WO2003053425A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070208087A1 (en) 2001-11-02 2007-09-06 Sanders Virginia J Compounds, compositions and methods for the treatment of inflammatory diseases
PT1511710E (pt) 2002-05-31 2014-02-26 Proteotech Inc Compostos, composições e métodos para o tratamento de doenças da amiloide e sinucleínopatias tais como doença de alzheimer, diabetes do tipo 2, e doença de parkinson
US20040167217A1 (en) * 2003-02-26 2004-08-26 Giovanni Scapagnini Neuroprotective effects of polyphenolic compounds
US20090227673A1 (en) * 2006-01-13 2009-09-10 Bao Ting Zhu Method and Composition for the Treatment of Parkinson's Disease
US8058309B2 (en) * 2006-12-04 2011-11-15 Novotyr Therapeutics Ltd. Protein kinase modulators and therapeutic uses thereof
US8637575B2 (en) 2008-06-05 2014-01-28 Novotyr Therapeutics Ltd. Modulators of protein kinase signaling
CN101941907B (zh) * 2010-05-28 2015-04-01 毛腾淑 4-叔丁基苄基-3,4-二羟基肉桂酸酯及其用途和制备方法
EP2629766B1 (de) 2010-10-18 2017-02-22 Chemigen Kombinationstherapie
WO2012068038A2 (en) * 2010-11-15 2012-05-24 Chemigen Caffeic acid derivatives and their use in improving neuronal cell viability
WO2015008206A1 (en) 2013-07-14 2015-01-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. Igf-1r signaling pathway inhibitors useful in the treatment of neurodegenerative diseases
CN107250108B (zh) 2015-02-05 2020-11-27 特尔诺沃有限公司 用于治疗癌症的irs/stat3双重调节剂与抗癌剂的组合

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2721398A1 (de) * 1976-05-19 1977-12-01 Ciba Geigy Ag Alkylphenol-stabilisatoren
JPS62294634A (ja) * 1986-04-11 1987-12-22 ワ−ナ−−ランバ−ト・コンパニ− ジアリ−ルアルカノイドおよびその製法
US4959503A (en) * 1986-04-11 1990-09-25 Warner-Lambert Company Diarylalkanoids having activity as lipoxygenase inhibitors
JPH0678286B2 (ja) * 1988-03-18 1994-10-05 三井東圧化学株式会社 ジヒドロカフェイン酸誘導体およびそれを有効成分として含有する治療剤
DE3920616A1 (de) * 1989-06-23 1991-01-03 Boehringer Mannheim Gmbh Arzneimittel, enthaltend di-tert.-butylhydroxyphenyl-derivate sowie neue derivate
DE4126662A1 (de) * 1991-08-13 1993-02-18 Boehringer Mannheim Gmbh Neue 3,5-di-tert.butyl-4-hydroxyphenyl-derivate, verfahren zu ihrer herstellung und arzneimittel
AU1463997A (en) * 1995-12-22 1997-07-17 Acea Pharmaceuticals, Inc. Subtype-selective nmda receptor ligands and the use thereof
WO1998009620A1 (en) * 1996-09-05 1998-03-12 Research Development Foundation INHIBITION OF NUCLEAR TRANSCRIPTION FACTOR NF-λB BY CAFFEIC ACID PHENETHYL ESTER (CAPE), DERIVATIVES OF CAPE, CAPSAICIN (8-METHYL-N-VANILLYL-6-NONENAMIDE) AND RESINIFERATOXIN
TW466115B (en) * 1996-12-10 2001-12-01 American Home Prod Pharmaceutical composition of antioxidant from equilenin
US6271199B2 (en) * 1997-02-15 2001-08-07 Millennium Pharmaceuticals, Inc. Treatment of infarcts
GB9801398D0 (en) * 1998-01-22 1998-03-18 Anggard Erik E Chemical compounds
WO2001021206A1 (en) * 1999-09-17 2001-03-29 Suntory Limited PREVENTIVES OR REMEDIES FOR MYOCARDITIS, DILATED CARDIOMYOPATHY AND CARDIAC INSUFFICIENCY CONTAINING NF-λB INHIBITORS AS THE ACTIVE INGREDIENT

Also Published As

Publication number Publication date
EP1461025A4 (de) 2009-07-29
EP1461025B1 (de) 2011-07-27
JP4511183B2 (ja) 2010-07-28
US8575215B2 (en) 2013-11-05
WO2003053425A1 (en) 2003-07-03
CA2466928A1 (en) 2003-07-03
US20100160433A1 (en) 2010-06-24
JP2005513100A (ja) 2005-05-12
TWI335220B (en) 2011-01-01
CN1589137A (zh) 2005-03-02
US20030139458A1 (en) 2003-07-24
TW200301100A (en) 2003-07-01
AU2002351341A1 (en) 2003-07-09
EP1461025A1 (de) 2004-09-29
CN100358515C (zh) 2008-01-02

Similar Documents

Publication Publication Date Title
DE60332137D1 (en) Cyclohexyl-sulphone als gamma-sekretase-inhibitoren
DE60218493D1 (de) Substituierte 7-aza-ä2.2.1übicycloheptane für die behandlung von krankheiten
DE69925256D1 (de) Trisubstituierte 1,3,5-triazine derivate zur behandlung von hiv infektionen
NO20041882L (no) Fremgangsmater for behandling av okulare neovaskulaere sykdommer.
BR0309665A (pt) Tratamento de deficiência de alfa-galactosidase a
BR0016681B1 (pt) composição amaciante de tecidos, e, método de tratamento de tecido.
ATE355079T1 (de) Behandlung von prostata-krebs mit anti-erbb2 antikörpern
ATE410430T1 (de) 2,3-dihydro-6-nitroimidazoä2,1- büoxazolverbindungen zur behandlung von tuberkulose
BR0114054A (pt) Método para tratar alergias usando pirazóis substituìdos
ATE438630T1 (de) 5-sulfanyl-4h-1,2,4-triazolderivate und deren verwendung zur behandlung von somatostatine vermittelten krankheiten
ATE384699T1 (de) 2,6-chinolinyl- und 2,6-naphthylderivate und deren verwendungen zur behandlung von vla-4 bezogenen krankheiten
TW200518769A (en) Use of calcitonin in osteoarthritis
DE69925865D1 (de) 4-(aminomethyl)-piperidinbenzamide zur behandlung von gastrointestinalen störungen
DE60130365D1 (de) Die Verwendung von Rosiglitazon zur Behandlung von psychiatrischen Erkrankungen.
NL1021504A1 (nl) Waterstofbehandelingsproces.
DE602004021847D1 (de) Verfahren zur prävention und behandlung von diabetes mit neurturin
ATE196083T1 (de) Verwendung von ferrioxamin-b zur behandlung septischen schocks
WO2004033423A3 (en) Anticancer compounds
DE50205466D1 (de) Substituierte 2,5-diamidoindole als ece-inhibitoren zur behandlung von kardiovaskulären erkrankungen
DK1438034T3 (da) Anvendelse af -phenyl-3-dimethylaminiopropanforbindelser til behandling af urininkontinens
ATE464048T1 (de) Behandlung von alzheimer-krankheit und verwandten zuständen
ITGE20020050A1 (it) Procedimento per il trattamento di filati mediante agugliatura.
ATE261724T1 (de) Antikonvulsive derivate zur behandlung von posttraumatischen stresserkrankungen
DE60201440D1 (de) Aryl-8-azabicyclo[3.2.1]octanes für die behandlung von depression
BR0314541A (pt) Tratamento de demência e doença de parkinson

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties